國家衛生研究院 NHRI:Item 3990099045/2746

NHRI > National Institute of Cancer Research > Jang-Yang Chang > Conference Papers/Meeting Abstract > Item 3990099045/2746

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2746

Title:	Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer
Authors:	Chao, Y;Yeh, KH;Chang, CJ;Chen, LT;Chao, TY;Wu, MF;Chang, CS;Chang, JY;Chung, CY;Kao, WY;Hsieh, RK;Cheng, AL
Contributors:	National Institute of Cancer Research
Abstract:	To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and folinic acid ( FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Oxaliplatin 65 mg m(-2) 2-h intravenous infusion, and 5-FU 2600 mg m(-2) plus FA 300 mg m(-2) 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January 2002, 55 patients were enrolled. The median age was 64 years (range: 22-75). In all, 52 patients (94.5%) had recurrent or metastatic disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved partial response, with an overall response rate of 56% (95% confidence interval (CI): 41.8-70.3%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median follow-up time of 24.0 months. Major grades 3-4 toxicities were neutropenia in 23 cycles (7.1%) and thrombocytopenia in 16 cycles (5.0%). Treatment was discontinued for treatment-related toxicities in nine patients (16.4%), of whom eight were due to oxaliplatin-related neurotoxicity. One patient (1.8%) died of neutropenic sepsis. This oxaliplatin-containing regimen is effective in the treatment of advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated.
Keywords:	Oncology
Date:	2004-08-02
Relation:	British Journal of Cancer. 2004 Aug;91(3):453-458.
Link to:	http://dx.doi.org/10.1038/sj.bjc.6601985
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0007-0920&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000222930400008
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=4243135036
Appears in Collections:	[Jang-Yang Chang] Conference Papers/Meeting Abstract [Li-Tzong Chen] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
000222930400008.pdf		105Kb	Adobe PDF	828	View/Open

Loading...